ProSciento Presents at the American Diabetes Association’s 77th Annual Scientific Sessions in San Diego

SAN DIEGO, June 6, 2017 – ProSciento Inc., metabolism-focused, full scope clinical R&D services provider, will present study results at this week’s American Diabetes Association (ADA) 77th Scientific Sessions, June 9-13 in San Diego.

Poster and oral presentations co-authored by ProSciento scientists include:

929-P. User Acceptability of a Long-Term, Fully-Implanted CGM System—Interim Clinical Results
General Poster Session in the Poster Hall
Saturday, June 10, 11:30am – 12:30pm

952-P. High-Risk Population Using Mobile Logging Application Shows Significant Reduction in LBGI
General Poster Session in the Poster Hall
Saturday, June 10, 11:30am – 12:30pm

1012-P. Comparative Pharmacokinetic and Pharmacodynamic Properties of Insulin “Basalin” and U.S.-Approved Originator Insulin Glargine in a Pilot Glucose Clamp Study in Patients with Type 1 Diabetes
General Poster Session in the Poster Hall
Saturday, June 10, 11:30am – 12:30pm

1067-P. Bimagrumab, an Activin Receptor Inhibitor, Improves Body Composition and Insulin Sensitivity in Insulin-Resistant Subjects
Saturday, June 10, 12:30pm – 1:30pm
Hall B (ePoster Theater A)

1096-P. A Bispecific Agonistic Antibody to FGF-R1/KlothoB Improves the Cardiometabolic Profile in Otherwise Healthy Obese Subjects—Preliminary Results from the First-in-Human Single Ascending Dose Study
Hall B – General Poster Session
Sunday, June 11, 12:00pm – 1:00pm

1121-P. Reduced Mean Glucose and Glycemic Variability with Co-administration of Basal-Bolus Pramlintide and Insulin in Type 1 Diabetes
Hall B – General Poster Session
Sunday, June 11, 12:00pm – 1:00pm

About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com

For business development inquires:
bd@prosciento.com
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com

in cat NOT

Stay Connected

Would you like to receive updates from ProSciento?

I'm interested in receiving: